Literature DB >> 16364053

Acute renal effects of intravenous bisphosphonates in the rat.

Thomas Pfister1, Elke Atzpodien, Bernd Bohrmann, Frieder Bauss.   

Abstract

Bisphosphonates are potent osteoclast inhibitors that have been associated with renal toxicity following rapid intravenous administration of high doses, which was hypothesised to be due to precipitation of bisphosphonate aggregates or complexes in the kidney. Five studies were conducted in rats investigating the characteristics of bisphosphonate-related acute renal effects. These studies included single intravenous injections of the nitrogen-containing bisphosphonates (1) ibandronate (1-20 mg/kg), or (2) zoledronate (1-10 mg/kg); (3) a single nephrotoxic dose of the non-nitrogen-containing bisphosphonate, clodronate (2 x 200 mg/kg intraperitoneal injection); (4) a single low dose of ibandronate (1 mg/kg); (5) a single high dose of zoledronate (10 mg/kg). Clinical biochemistry and kidney histopathology were performed 1 and/or 4 days after bisphosphonate dosing. The proximal convoluted tubules were the primary target for renal injury. Tubular degeneration and single cell necrosis of the these tubules were observed with all three bisphosphonates on the fourth, but not the first day after dosing. Differences between the bisphosphonates in the type and/or localisation of the lesions were apparent. Granular deposits in the lumen of distal tubules were apparent with the highest dose of zoledronate (10 mg/kg). However, intraluminal debris was proteinaceous with no evidence of any precipitation of bisphosphonate, or formation of aggregates or complexes in the kidney. Generally, biochemical parameters of renal safety and urinary enzymes did not differ significantly from controls. In summary, bisphosphonate-related renal changes did not appear to be due to the precipitation, aggregation or complexation of bisphosphonate, and biochemical parameters of renal safety did not reliably detect this renal injury.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16364053     DOI: 10.1111/j.1742-7843.2005.pto_160.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  10 in total

1.  Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease.

Authors:  E A Swallow; M W Aref; N Chen; I Byiringiro; M A Hammond; B P McCarthy; P R Territo; M M Kamocka; S Winfree; K W Dunn; S M Moe; M R Allen
Journal:  Osteoporos Int       Date:  2018-06-11       Impact factor: 4.507

Review 2.  Managing Musculoskeletal and Kidney Aging: A Call for Holistic Insights.

Authors:  Pierre-Emmanuel Cailleaux; Martine Cohen-Solal
Journal:  Clin Interv Aging       Date:  2022-05-04       Impact factor: 3.829

3.  Zoledronic Acid-Associated Fanconi Syndrome in Patients With Cancer.

Authors:  Ignacio Portales-Castillo; David B Mount; Sagar U Nigwekar; Elaine W Yu; Helmut G Rennke; Shruti Gupta
Journal:  Am J Kidney Dis       Date:  2022-02-24       Impact factor: 11.072

4.  Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.

Authors:  Ingo J Diel; Rudolf Weide; Hubert Köppler; Lucia Antràs; Michael Smith; Jesse Green; Neil Wintfeld; Maureen Neary; Mei Sheng Duh
Journal:  Support Care Cancer       Date:  2008-12-17       Impact factor: 3.603

5.  Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study.

Authors:  Danielle E Robinson; M Sanni Ali; Victoria Y Strauss; Leena Elhussein; Bo Abrahamsen; Nigel K Arden; Yoav Ben-Shlomo; Fergus Caskey; Cyrus Cooper; Daniel Dedman; Antonella Delmestri; Andrew Judge; Muhammad Kassim Javaid; Daniel Prieto-Alhambra
Journal:  Health Technol Assess       Date:  2021-03       Impact factor: 4.014

Review 6.  Bisphophonates in CKD patients with low bone mineral density.

Authors:  Wen-Chih Liu; Jen-Fen Yen; Cheng-Lin Lang; Ming-Tso Yan; Kuo-Cheng Lu
Journal:  ScientificWorldJournal       Date:  2013-12-31

7.  The role of vitamin E in the prevention of zoledronic acid-induced nephrotoxicity in rats: a light and electron microscopy study.

Authors:  İbrahim Unal Sert; Ozcan Kilic; Murat Akand; Lutfi Saglik; Mustafa Cihat Avunduk; Esra Erdemli
Journal:  Arch Med Sci       Date:  2016-05-30       Impact factor: 3.318

8.  Risedronate Attenuates Podocyte Injury in Phosphate Transporter-Overexpressing Rats.

Authors:  Yohei Asada; Takeshi Takayanagi; Tsukasa Kawakami; Eisuke Tomatsu; Atsushi Masuda; Yasumasa Yoshino; Sahoko Sekiguchi-Ueda; Megumi Shibata; Tomihiko Ide; Hajime Niimi; Eishin Yaoita; Yusuke Seino; Yoshihisa Sugimura; Atsushi Suzuki
Journal:  Int J Endocrinol       Date:  2019-10-23       Impact factor: 3.257

Review 9.  What Animal Models Have Taught Us About the Safety and Efficacy of Bisphosphonates in Chronic Kidney Disease.

Authors:  Matthew R Allen; Mohammad W Aref
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.163

10.  Inhibitory actions by ibandronate sodium, a nitrogen-containing bisphosphonate, on calcium-activated potassium channels in Madin-Darby canine kidney cells.

Authors:  Sheng-Nan Wu; Hui-Zhen Chen; Yu-Hung Chou; Yan-Ming Huang; Yi-Ching Lo
Journal:  Toxicol Rep       Date:  2015-08-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.